Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Study to Evaluate the Efficacy and Safety of CS060380 Tablets in Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH) and Obesity.

NCT07466017 is registered in ClinicalTrials.gov with Cascade Pharmaceuticals, Inc as lead sponsor.

NCT NCT07466017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07466017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Study to Evaluate the Efficacy and Safety of CS060380 Tablets in Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH) and Obesity.
Lead sponsor
Cascade Pharmaceuticals, Inc
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 2, 2026
Completion date
July 30, 2027
Enrollment
130 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

metabolic dysfunction-associated steatohepatitis (mash), obesity